One of the Largest European Vaccine Production Capacities Planned

  • Author: ChemistryViews
  • Published: 17 February 2021
  • Copyright: Wiley-VCH GmbH
  • Associated Suppliers: AstraZeneca plc, Cambridge, UK
thumbnail image: One of the Largest European Vaccine Production Capacities Planned

AstraZeneca and IDT Biologika plan to accelerate the production of COVID-19 Vaccine AstraZeneca (formerly called AZD1222). Details of the agreement are to be finalized. Both companies plan to invest in capacity expansion at IDT Biologika’s production site in Dessau, Germany to build up to five 2,000-litre bioreactors capable of making tens of millions of doses per month of AstraZeneca’s COVID-19 vaccine. The new assets are estimated to be operational by the end of 2022.

The new facilities could also be used by manufacture of other vaccines sharing a similar manufacturing process. IDT Biologika will have among the largest vaccine manufacturing capacities of its kind in Europe and play an important part in ensuring Europe’s future vaccine supply independence.

On 29 January, COVID-19 Vaccine AstraZeneca was granted a conditional marketing authorization (CMA) in the European Union (EU) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. On 15 February, the vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older, including those over 65.

COVID-19 Vaccine AstraZeneca was co-invented by the University of Oxford, UK, and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.


 

 



 

Article Views: 482

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH